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;Reply to Nevin
We agree with Nevin [1] that the post-
marketing surveillance methodology of
our article [2] has similarities with the
analysis published in 1998 by Vanhau-
were and colleagues [3]. We appropriate-
ly referenced the aforementioned paper
in our publication. Our methodology
however, differs in that we separately an-
alyzed maternal, paternal, and both-
parent exposure to meﬂoquine, and the
time period for our study was signiﬁ-
cantly longer (1986–2010) [2]. Further-
more, for comparison, we provided
background rates for pregnancy out-
comes in the general population.
We disagree that the use of this meth-
odology should limit the usefulness of
our data. Pregnant women are routinely
excluded from clinical trials. For many
medications that are initially contraindi-
cated in pregnancy, the use of drug safety
databases constitutes an important tool
for assessing safety during pregnancy.
Our analysis provides physicians and pa-
tients with information for the evaluation
of beneﬁt and risk in women of child-
bearing potential exposed to meﬂoquine.
Our main outcome measures were
descriptive birth defect reporting preva-
lence and types of malformations. We
also provided limited data on fetal loss
and reviewed all literature on this
subject including the references that
Nevin cites in his letter and other refer-
ences that he omitted to mention. Fetal
loss or miscarriage is difﬁcult to quanti-
fy in any population due to ascertain-
ment bias [4], and epidemiological data
from previous studies show varying
results: a Thai study reported an in-
creased risk of miscarriage in 159 meﬂo-
quine prophylaxis users [5], whereas a
second larger study in Malawi showed no
increase in stillbirths in women receiving
meﬂoquine prophylaxis (n = 1032) [6].
Nevin refers to the use of sulfadoxine-
pyrimethamine as intermittent treatment
in the developing world for pregnant
women. This is a separate topic that we did
not address. Our paper is concerned with
malaria prophylaxis in pregnant women
from industrialized countries who cannot
defer travel to malaria-endemic areas.
Dr Nevin’s other letter [7] suggests a
biological mechanism linking meﬂo-
quine to pregnancy loss. This proposed
mechanism warrants further inquiry but
because it is a hypothesis, based on non-
clinical data, it should be interpreted
with caution in the human context.
Various factors, such as age and expo-
sure to malaria, could contribute to the
loss of pregnancy in women traveling to
endemic areas. A large study from
Denmark showed that the risk of spon-
taneous abortion in women aged 20–24
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is 8%–9%, rising with age to 74.7% in
women aged >45 years [8]. Exposure to
malaria further increases the risk of fetal
loss. A recent analysis found that a
single episode of Plasmodium falcipa-
rum or Plasmodium vivax malaria could
cause miscarriage [9].
Malaria in women of childbearing po-
tential needs to be prevented. The recent
data on imported malaria in the US
report 41 cases in pregnant women in
2010, the majority traveling to Africa
and not using a chemoprophylaxis [10].
In 2011, the Food and Drug Administra-
tion reclassiﬁed meﬂoquine from preg-
nancy category C to category B. The
Centers for Disease Control and Preven-
tion recommends meﬂoquine prophy-
laxis in all trimesters of pregnancy for
women who cannot defer travel to high-
risk, malaria-endemic areas [11].
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